Tiziana life sciences announces an interview on clinical improvements for 2nd spms patient

New york, june 09, 2022 (globe newswire) -- tiziana life sciences (nasdaq: tlsa) ("tiziana" or the "company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug administration, today announces an interview with chief executive officer and chief scientific officer kunwar shailubhai, phd and proactive investors discussing the positive clinical results from the second patient with secondary progressive multiple sclerosis (spms) in the ongoing study as part of an expanded access program at the brigham and women's hospital (bwh), boston, ma.
TLSA Ratings Summary
TLSA Quant Ranking